Dose Comparison of Remifentanil and Alfentanil for Loss of Consciousness
- 1 August 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 87 (2) , 253-259
- https://doi.org/10.1097/00000542-199708000-00011
Abstract
Background: This study evaluated the efficacy and safety of remifentanil, a potent mu agonist opioid with a rapid onset and offset of effect, as a sole induction agent for loss of consciousness (LOC) and compared it with alfentanil. Methods: Remifentanil and alfentanil were administered intravenously over 2 min in ascending doses (remifentanil 2, 3, 4, 5, 6, 8, 10, 15, 20 microg/kg; alfentanil 40, 60, 80, 100, 120, 160, 200 microg/kg) to unpremedicated healthy patients. Patients were observed for rigidity and LOC for 30 s after the end of infusion. If patients had not lost consciousness, 2 mg x kg(-1) x min(-1) thiopental was administered until LOC was achieved. Arterial blood samples, obtained at specified time intervals, were analyzed for remifentanil and alfentanil whole-blood concentration. Blood pressure and heart rate were also recorded at preset time intervals. Results: Neither drug could reliably produce LOC. With both drugs, there was a dose-dependent decrease in thiopental requirements and a dose-dependent increase in the incidence and severity of rigidity (P < 0.05). The median effective dose (ED50) for LOC with remifentanil was 12 microg/kg, and for alfentanil it was 176 mcrog/kg. The median effective concentration (EC50; whole-blood concentration) of remifentanil was 53.8 ng/ml and for alfentanil it was 1,012 ng/ml. Minimal hemodynamic changes were observed after either drug was given. Conclusions: Remifentanil is 15 times more potent than alfentanil, based on the ED50 to achieve loss of response to a verbal command and 20 times more potent than alfentanil based on the EC50. Neither opioid is suitable as a sole induction agent.Keywords
This publication has 14 references indexed in Scilit:
- Determination of alfentanil and noralfentanil in human plasma by gas chromatography—mass spectrometryJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Determination of remifentanil in human blood by liquid-liquid extraction and capillary GC-HRMS-SIM using a deuterated internal standardJournal of Pharmaceutical and Biomedical Analysis, 1994
- Pharmacokinetics of Remifentanil (GI87084B) and Its Major Metabolite (GI90291) in Patients Undergoing Elective Inpatient SurgeryAnesthesiology, 1993
- Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra-Short-Acting OpioidAnesthesia & Analgesia, 1993
- The Pharmacokinetics of the New Short-acting Opioid Remifentanil (GI87084B) in Healthy Adult Male VolunteersAnesthesiology, 1993
- Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgesicsJournal of Medicinal Chemistry, 1991
- ED50 of Alfentanil for Induction of Anesthesia in Unpremedicated Young AdultsAnesthesiology, 1984
- The Enflurane Sparing Effect of Morphine, Butorphanol, and NalbuphineAnesthesiology, 1982
- The Anesthetic Potency of Fentanyl in Terms of Its Reduction of Enflurane MACAnesthesiology, 1982
- Anesthetic Induction with AlfentanilAnesthesia & Analgesia, 1982